Quick Answer
Dogwood Therapeutics, Inc. reported Net Income of -$34.26 million for fiscal year 2025.
Dogwood Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$34.26M -177.4% |
-$12.35M -133.2% |
-$5.30M +56.8% |
-$12.25M +23.3% |
-$15.96M -54.3% |
-$10.35M |
| Diluted EPS | -$7.13 +43.1% |
-$12.52 -77.6% |
-$7.05 -535.1% |
-$1.11 +42.2% |
-$1.92 +8.6% |
-$2.10 |
| Total Assets | $90.17M -4.4% |
$94.31M +2164.1% |
$4.17M -50.2% |
$8.37M -46.9% |
$15.78M -49.9% |
$31.47M |
| Cash and Equivalents | $6.52M -56.1% |
$14.85M +347.6% |
$3.32M -52.8% |
$7.03M -49.8% |
$14.01M -53.0% |
$29.80M |
| Stockholders Equity | $74.90M +839.8% |
-$10.12M -365.9% |
$3.81M -48.0% |
$7.33M -49.5% |
$14.50M -51.6% |
$29.94M +696.7% |
| R&D Expense | $21.87M +519.3% |
$3.53M +104.3% |
$1.73M -78.6% |
$8.07M -25.3% |
$10.80M +5464.4% |
$194.0K |
| Operating Income | -$27.97M -128.7% |
-$12.23M -124.5% |
-$5.45M +55.8% |
-$12.32M +21.3% |
-$15.64M -56.3% |
-$10.01M |
| Shares Outstanding | 29.74M +7.2% |
27.76M +3503.4% |
770,317 -95.8% |
18.33M +120.0% |
8.33M +0.3% |
8.31M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$15.74M | -590.3% | -313.5% |
| Diluted EPS | September 30, 2025 | -$8.20 | -300.0% | -312.1% |
| Total Assets | September 30, 2025 | $91.99M | +3929.0% | -4.9% |
| Cash and Equivalents | September 30, 2025 | $10.13M | +396.5% | -24.4% |
| Stockholders Equity | September 30, 2025 | $7.26M | +664.5% | +5.5% |
| R&D Expense | September 30, 2025 | $14.52M | +2613.4% | +465.0% |
| Operating Income | September 30, 2025 | -$15.81M | -587.0% | -303.0% |
| Shares Outstanding | September 30, 2025 | 2.29M | -91.7% | +20.0% |
- Dogwood Therapeutics, Inc. reported Net Income of -$34.26 million for fiscal year 2025.
- Dogwood Therapeutics, Inc. showed a decrease of -177.4% in Net Income compared to the prior fiscal year.
- Dogwood Therapeutics, Inc. reported Diluted EPS of $7.13 per share (loss) for fiscal year 2025.
- Dogwood Therapeutics, Inc. showed an increase of +43.1% in Diluted EPS compared to the prior fiscal year.
- Dogwood Therapeutics, Inc. reported Total Assets of $90.17 million for fiscal year 2025.
- Dogwood Therapeutics, Inc. showed a decrease of -4.4% in Total Assets compared to the prior fiscal year.
- Dogwood Therapeutics, Inc. reported Cash and Equivalents of $6.52 million for fiscal year 2025.
- Dogwood Therapeutics, Inc. showed a decrease of -56.1% in Cash and Equivalents compared to the prior fiscal year.
- Dogwood Therapeutics, Inc. reported Stockholders Equity of $74.90 million for fiscal year 2025.
- Dogwood Therapeutics, Inc. showed an increase of +839.8% in Stockholders Equity compared to the prior fiscal year.
- Dogwood Therapeutics, Inc. reported R&D Expense of $21.87 million for fiscal year 2025.
- Dogwood Therapeutics, Inc. showed an increase of +519.3% in R&D Expense compared to the prior fiscal year.
- Dogwood Therapeutics, Inc. reported Operating Income of -$27.97 million for fiscal year 2025.
- Dogwood Therapeutics, Inc. showed a decrease of -128.7% in Operating Income compared to the prior fiscal year.
- Dogwood Therapeutics, Inc. reported Shares Outstanding of 29.74 million shares for fiscal year 2025.
- Dogwood Therapeutics, Inc. showed an increase of +2132.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: